CEL-SCI CORPORATION Debt Conversion, Converted Instrument, Amount
CEL-SCI CORPORATION (CVM) reported Debt Conversion, Converted Instrument, Amount of $0 for the 9-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2019-08-14
- CEL-SCI CORPORATION debt conversion, converted instrument, amount for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION debt conversion, converted instrument, amount for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION debt conversion, converted instrument, amount for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION debt conversion, converted instrument, amount for the quarter ending 2018-06-30 was $2.11M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month |
|---|---|---|---|
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | $0.00 derived: sum of 2 quarters · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 |
| 2019-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | $0.00 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-02-14 | ||
| 2018-06-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | $2.22M derived: sum of 2 quarters · filed 2019-08-14 | $2.29M 10-Q · filed 2019-08-14 |
| 2018-03-31 | $109.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | $184.30K 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $75.00K 10-Q · filed 2019-02-14 | ||
| 2017-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | $0.00 derived: sum of 2 quarters · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 |
| 2017-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | $0.00 10-Q · filed 2018-05-15 | |
| 2016-12-31 | $0.00 10-Q · filed 2018-02-12 | ||
| 2015-12-31 | $24.84K 10-Q/A · filed 2017-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |